Canada extends Iraq, Ukraine military training missions

Canada's Defense Minister Harjit Sajjan speaks during a news conference with Foreign Minister Chrystia Freeland in Ottawa, Ontario, Canada, on March 18, 2019. (Reuters)
Updated 19 March 2019

Canada extends Iraq, Ukraine military training missions

  • Chrystia Freeland: "Ukraine can continue to count on Canada's unwavering support"
  • In Iraq, Canada will keep 250 special forces troops training Iraqi security forces

OTTAWA: Canada's defense and foreign ministers jointly announced Monday the extensions of military training missions in Iraq and Ukraine.
Both had been slated to wrap up at the end of March, but security concerns persist.
In Iraq, Canada will keep 250 special forces troops advising and training Iraqi security forces, plus several attack helicopters, as part of the US-led coalition against the Islamic State mission until the end of March 2021.
The number of troops deployed could ramp up to 850, if needed, and they will also help neighboring Jordan and Lebanon build their respective security capabilities, said officials.
Complementing those efforts, Canada last November assumed command of a new NATO mission. It has been contributing air power, medical support and help in training Iraqi forces since 2014.
"We have made significant and lasting progress, but we recognize that more work is needed. Now we must ensure that Daesh can never rebuild and threaten the safety of Iraq," Defense Minister Harjit Sajjan told a press conference, using an Arabic acronym for IS.
In Ukraine, some 200 Canadian troops will continue to provide arms, military engineering, logistics, military policing, and medical training until the end of March 2022.
Since 2015, Canada has so far trained nearly 11,000 Ukrainian soldiers.
Canada will also host a third Ukraine reform conference in Toronto on July 2-4.
"Ukraine can continue to count on Canada's unwavering support," Foreign Minister Chrystia Freeland said.
"It's very important to send a strong message to Ukraine, to the people of Ukraine, and to the international community that the invasion of Crimea and the annexation of Crimea are a grave breach of international law," she added.


US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

Updated 55 min 37 sec ago

US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.